UNSPSC 51332904: Nicergoline tartrate

This classification denotes an alpha-adrenergic blocking agent C24H26BrN3O3.C6H10O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J7P36Z4900, chemically known as ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, 5-bromo-3-pyridinecarboxylate (ester), (8.beta.)-, (2r,3r)-2,3-dihydroxybutanedioate (salt), but more generally known as nicergoline tartrate, which bears US NIH Compound Identifier 134961.

UNSPSC 51332904 Nicergoline tartrate is a Commodity code that nominally describes a single pharmaceutical active ingredient, but recent state and local solicitations tagged under this code show little alignment with nicergoline itself. Instead, the opportunities posted under the code involve procurement of naloxone kits, safe drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and pharmacy benefit management services — a broad and loosely related set of pharmaceutical and health-supply acquisitions that do not correspond to nicergoline tartrate specifically. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The work being solicited ranges from annual purchases of naloxone and drug disposal equipment for community health initiatives to statewide generic pharmaceutical sourcing through established wholesale networks and exploratory market research on direct-to-manufacturer prescription programs.

The geographic spread of recent activity includes Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023 — note the date discrepancy in the source) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract awards effective July 1, 2026 and a two-year initial term. The code shows recent activity but exhibits a significant mismatch between its nominal scope (nicergoline tartrate) and what state and local buyers are actually procuring under it.